Company intelligence / Profile preview

Q2i

Boston, Massachusetts, United States

Ownership: Private
Development stage: Other

Overview

Q2i’s PARCA technology has completed a successful NIH Phase I trial and is now in Phase II to further evaluate its efficacy in improving community supervision success. The company’s digital platforms are deployed commercially to support medication-assisted treatment programs and contingency management for substance use disorders. Early results show improved patient-provider communication, increased engagement with treatment plans, and measurable improvements in program fidelity and outcomes.

Therapeutic areas: Psychiatry
Modalities: Device (mobile application/platform)Non-pharmacological therapy (digital behavioral interventions)Telehealth platform
Industry: Digital Health Medical Devices

Partnerships

MaineHealthNational Institutes of HealthKing’s College LondonUK GovernmentMassachusetts University

Beyond the preview

Go deeper on Q2i.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Q2i.

Explore the full profile